The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
Authors:
- 1 August 2008
- journal article
- review article
- Published by Wiley in Human Mutation
- Vol. 29 (8) , 992-1006
Abstract
The RAS proteins and their downstream pathways play pivotal roles in cell proliferation, differentiation, survival and cell death, but their physiological roles in human development had remained unknown. Noonan syndrome, Costello syndrome, and cardio‐facio‐cutaneous (CFC) syndrome are autosomal dominant multiple congenital anomaly syndromes characterized by a distinctive facial appearance, heart defects, musculocutaneous abnormalities, and mental retardation. A variety of mutations in protein tyrosine phosphatase, non‐receptor type 11(PTPN11) has been identified in 50% of Noonan patients. Specific mutations in PTPN11 have been identified in LEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness) syndrome. In 2005, we discovered Harvey‐RAS (HRAS) germline mutations in patients with Costello syndrome. This discovery provided a clue to identification of germline mutations in Kirsten‐RAS (KRAS), BRAF and mitogen‐activated protein kinase kinase 1 and 2 (MAP2K1/MAP2K2) in patients with CFC syndrome. These genes encode molecules in the RAS/RAF/MEK/extracellular signal‐regulated kinase (ERK) pathway, leading to a new concept that clinically related disorders, i.e., Noonan, Costello, and CFC syndromes are caused by dysregulation of the RAS/mitogen activated protein kinase (MAPK) pathway. In the present review, we summarize mutations in HRAS, KRAS, BRAF, MAP2K1/2, and PTPN11, the phenotypes of patients with these mutations, the functional properties of mutants and animal models. Finally we suggest that disorders with mutations of molecules in the RAS/MAPK cascade (Noonan, LEOPARD, Costello, and CFC syndromes and neurofibromatosis type I) may be comprehensively termed “the RAS/MAPK syndromes.” Details on mutations will be updated in the RAS/MAPK Syndromes Homepage (www.medgen.med.tohoku.ac.jp/RasMapk syndromes.html). Hum Mutat 0, 1–15, 2008.Keywords
This publication has 118 references indexed in Scilit:
- Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndromeNature Genetics, 2006
- Germline gain-of-function mutations in SOS1 cause Noonan syndromeNature Genetics, 2006
- Somatic mosaicism for an HRAS mutation causes Costello syndromeAmerican Journal of Medical Genetics Part A, 2006
- Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome PhenotypeThe American Journal of Human Genetics, 2006
- Germline KRAS mutations cause Noonan syndromeNature Genetics, 2006
- Germline mutations in HRAS proto-oncogene cause Costello syndromeNature Genetics, 2005
- Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionNature Structural & Molecular Biology, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Site-Specific Incorporation of a Phosphotyrosine Mimetic Reveals a Role for Tyrosine Phosphorylation of SHP-2 in Cell SignalingMolecular Cell, 2001